Encouraging Data from Phase I Studies of Astex’s Anti-Cancer Drugs AT7519, AT9283 and AT13387 to be Presented at EORTC-NCI-AACR Annual Meeting

Encouraging Data from Phase I Studies of Astex’s Anti-Cancer Drugs AT7519, AT9283 and AT13387 to be Presented at EORTC-NCI-AACR Annual Meeting